In this analysis, researchers aimed to quantify and bring attention to the time burden experienced by cancer patients enrolled in phase 2 clinical trials.

The study will enrol 160 patients with IPF who have not previously received treatment.

Please provide your email address to receive an email when new articles are posted on . One in six participants in phase 2 cancer trials received a therapy that gained FDA approval. The results ...

Avalyn, a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, today announced the initiation of the AURA ...

Phase 2 trial launched for verekitug in COPD, expanding treatment indications for severe respiratory conditions. Top data expected in 2026. Upstream Bio, Inc. has initiated a global Phase 2 clinical ...

“It’s deeply rewarding to see DZ-002 advance into Phase 2 trials, marking a promising step forward in cancer treatment and offering hope for improved patient outcomes,” says Professor of Chemistry ...

Bria-IMT plus a checkpoint inhibitor showed a 52% one-year survival rate in metastatic breast cancer patients, surpassing standard therapy outcomes. The treatment was well-tolerated, with no ...

SELLAS Life Sciences reports successful Phase 2 trial results for SLS009 in relapsed/refractory AML, exceeding response and survival rates. SELLAS Life Sciences Group has announced that its Phase 2 ...